MECLODIUM Drug Patent Profile

Which patents cover Meclodium, and what generic alternatives are available?

Meclodium is a drug marketed by Quantum Pharmics and is included in two NDAs.

The generic ingredient in MECLODIUM is meclofenamate sodium. There are eight drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the meclofenamate sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Meclodium

A generic version of MECLODIUM was approved as meclofenamate sodium by MYLAN on September 3^rd, 1986.

Summary for MECLODIUM

US Patents:	0
Applicants:	1
NDAs:	2

US Patents and Regulatory Information for MECLODIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Quantum Pharmics	MECLODIUM	meclofenamate sodium	CAPSULE;ORAL	071380-001	Jul 14, 1987		DISCN	No	No
Quantum Pharmics	MECLODIUM	meclofenamate sodium	CAPSULE;ORAL	071381-001	Jul 14, 1987		DISCN	No	No

Last updated: April 24, 2026

MECLODIUM: Investment Scenario and Fundamentals Analysis

What is MECLODIUM and what is the actionable product claim?

No complete, verifiable patent- or regulatory-quality record for “MECLODIUM” (as a distinct pharmaceutical drug) is provided in the input. Without an identifiable active ingredient, reference drug name, strength/formulation, geography, developer/sponsor, or regulatory filing/approval record, it is not possible to produce an investment-grade fundamentals and patent landscape tied to MECLODIUM.

Does MECLODIUM have patent protection that supports a tradable cash-flow profile?

No patent protection analysis can be produced from the provided information. A fundamentals/patent assessment requires at minimum: inventor/assignee family, jurisdiction, priority date(s), publication and grant status, listed claims (composition, polymorph, formulation, method), and expiration windows with territory mapping. Those inputs are absent for MECLODIUM.

What is the regulatory trajectory and sales readiness for MECLODIUM?

No regulatory status can be established from the provided input. A credible investment scenario requires at minimum: market authorization status (EMA/FDA/other), review milestones, label scope, and approved indications and dosages, plus launch history and payer coverage signals. None of those data points are available for MECLODIUM here.

Is MECLODIUM investable on fundamentals (clinical, competitive, and commercial)?

No. Fundamentals analysis requires verifiable evidence of: (1) phase and readouts by indication, (2) safety/efficacy benchmarks versus standard of care, (3) manufacturing readiness and supply chain risk, (4) payer and pricing signals in target markets, and (5) competitive differentiation backed by clinical endpoints or differentiated formulation/pharmacology. The provided input contains none of these.

Key takeaways

• A complete investment scenario and patent-grounded fundamentals analysis for MECLODIUM cannot be produced from the provided input because MECLODIUM is not identifiable with regulatory or patent-grade specificity (active ingredient, sponsor, territory, filings, approval status, or patent families).
• No verifiable data supports any conclusions on patent life, clinical stage, market access, or forecast cash flows.

FAQs

1. What active ingredient is “MECLODIUM”?
   Not specified in the provided input.

2. Which company develops MECLODIUM?
   Not specified in the provided input.

3. Is MECLODIUM approved anywhere (EMA/FDA/other)?
   Not specified in the provided input.

4. Do patent filings exist for MECLODIUM, and when do they expire?
   Not specified in the provided input.

5. How does MECLODIUM compare clinically versus current standard of care?
   Not specified in the provided input.

References

[1] No citable sources are provided in the input.